View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 11, 2022

Moderna and Rovi Pharma recall Covid-19 vaccine doses

The vaccines from the lot were supplied in Norway, Poland, Portugal, Spain and Sweden from 13 to 14 January this year.

Moderna and Rovi Pharma have recalled a batch of 764,900 doses of the Moderna Covid-19 vaccine, Spikevax. 

The move comes after a foreign body was detected in one of the vials from the batch produced at Rovi’s contract manufacturing site in Spain. 

The company noted that the contaminated vial was punctured and was not used for administration to people.

Moderna’s marketing authorisation holders Moderna Biotech Spain and Rovi were informed of the issue through a complaint on the product from an inoculation centre in Málaga, Spain. 

Furthermore, the vaccine vial was sent for forensic analysis and study. 

The vaccines from the lot were supplied in Norway, Poland, Portugal, Spain and Sweden from 13 to 14 January this year.

Moderna carried out a collective search of its global safety database and no safety issues were reported in people who took the vaccine from this lot. 

So far, no safety or efficacy issues were reported.

Moderna noted that the foreign body found in a vial does not present a risk to other vials in the lot and might not impact the substantial benefit/risk profile of the shot.

More than 900 million doses of the vaccine have so far been administered globally.

In a statement, Rovi said: “Given the company’s priority to assure quality and out of an abundance of caution, this lot is being recalled. 

“Moderna is proactively communicating with health authorities as the investigation proceeds.” 

In March this year, Moderna entered an agreement with the Ministry of Health, Labour and Welfare of Japan to supply an additional 70 million doses of its Covid-19 booster vaccine or an updated booster vaccine candidate.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU